The Tissue Thromboplastin Inhibition Test in the Detection of Lupus Anticoagulants: Importance of a Correction Factor Eliminating the Influence of Fibrinogen Level

Summary

Tissue thromboplastin inhibition test (TTI) is a highly sensitive but poorly specific test used in the diagnosis of lupus anticoagulant (LA) which is usually requested for patient with inflammatory status. Therefore, we investigated the influence of fibrinogen level on TTI using Recombiplastin (Ortho), Neoplastine (Diagnostica Stago) and Throm-borel S (Behring), in a group of 84 patients with fibrinogen levels ranging from 1.6 to 11.8 g/1. The highly significant (p<0.0001) positive correlation observed between fibrinogen level and TTI with the 3 thromboplastins allowed the calculation of a new TTI value corrected for fibrinogen level named TTIfg. TTIfg was defined as TTI - (“S” × fibrinogen level) where “S” was the slope of the regression line defining TTI as a function of fibrinogen values. In the group studied, the low TTI specificity, respectively 64%, 67% and 75% with Recombiplastin, Neoplastine and Thromborel S, was greatly improved to respectively 95%, 93% and 95% when results were expressed as TTIfg. TTIfg remained as sensitive as TTI when evaluated in a group of 38 patients with previously diagnosed LA.

• References

• 1 Exner T, Triplett DA, Tabemer D, Machin SJ. Guidelines for testing and revised criteria for lupus anticoagulants. SSC Subcommitee for the standardization of lupus anticoagulant. Thromb Haemost 1991; 65: 320-322
• 2 Thiagarajan P, Shapiro SS, De Marco L. Monoclonal immunoglobulin MX coagulation inhibitor with phospholipid specificity. Mechanism of a lupus anticoagulant. J Clin Invest 1980; 66: 397-405
• 3 Pengo V, Thiagarajan P, Shapiro SS, Heine MJ. Immunological specificity and mechanism of action of IgG lupus anticoagulant. Blood 1987; 70: 6976
• 4 Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RFA. Lupus anticoagulant IgG’s (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 1991; 66: 629-632
• 5 Roubey RA, Pratt CW, Buy on JP, Winfield JB. Lupus anticoagulant activity of autoimmune antiphospholipid antibodies is dependent upon (32-glycoprotein I. Clin Invest 1992; 90: 1100-1104
• 6 Oosting JD, Derksen RHWM, Entjes HTI, Bouma BN, de Groot PG. Lupus anticoagulant is frequently dependent on the presence of (32-glycoprotein I. Thromb Haemost 1992; 67: 499-502
• 7 Love PE, Santoro SA. Antiphospholipid antibodies: Anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med 1990; 112: 682-698
• 8 Ginsberg JS, Brill-Edwards P, Johnston M, Denburg JA, Andrew M, Burrows RF, Bensen W, Cividino A, Long AA. Relationship of antiphospholipid antibodies to pregnancy loss in patients with systemic lupus erythematosus: A cross-sectional study. Blood 1992; 80: 975-980
• 9 Lesperance B, David M, Rauch J, Infante-Rivard C, Rivard GE. Relative sensitivity of different tests in the detection of low titer lupus anticoagulants. Thromb Haemost 1988; 60: 217-219
• 10 Lo SCL, Oldmeadow MJ, Howard MA, Firkin BG. Comparison of laboratory tests used for identification of the lupus anticoagulant. Am J Hematol 1989; 30: 213-220
• 11 Exner T, Triplett DA, Taberner DA, Howard MA, Harris EN. Comparison of test methods for the lupus anticoagulant: International survey on lupus anticoagulants-I (ISLA-1). Thromb Haemost 1990; 64: 478-484
• 12 Working group on Hemostasis of the Societe Frangaise de Biologie Clinique. Comparison of a standardized procedure with current laboratory practices for the detection of lupus anticoagulant in France. Thromb Haemost 1993 70. 781-786
• 13 Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on lupus anticoagulant/antiphospholipid antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995; 74: 1185-1190
• 14 Schleider MA, Nachman RL, Jaffe EA, Coleman M. A clinical study of the lupus anticoagulant. Blood 1976; 48: 499-509
• 15 Triplett DA, Brandt JT, Kaczor D, Schaeffer J. Laboratory diagnosis of lupus inhibitors: a comparison of the tissue thromboplastin inhibition procedure with a new platelet neutralization procedure. Am J Clin Pathol 1983; 79: 678-682
• 16 Rosove MH, Ismail M, Koziol BJ, Runge A, Kasper CK. Lupus anticoagulants: improved diagnosis with a kaolin clotting time using rabbit brain phospholipid in standard and high concentrations . Blood 1986; 68: 472-478
• 17 Liu HW, Wong KL, Lin CK, Wong WS, Tse PWT, Chan GTC. The reappraisal of dilute thromboplastin inhibition test in the diagnosis of lupus anticoagulant. Br J Haematol 1989; 72: 229-234
• 18 Arnout J, Vanrusselt M, Huybrechts E, Vermylen J. Optimization of the dilute prothrombin time for the detection of the lupus anticoagulant by use of a recombinant tissue thromboplastin. Brit J Haematol 1994; 87: 94-99
• 19 Robert A. Two different incubation times for the activated partial thromboplastin time (APTT): a new criterion for diagnosis of lupus anticoagulant. Thromb Haemost 1994; 71: 220-224
• 20 Brandt JT, Triplett DA, Musgrave K, Orr C. The sensitivity of different coagulation reagents to the presence of lupus anticoagulants. Arch Pathol Lab Med 1987; 11: 120-124
• 21 Brandt JT, Triplett DA, Rock WA, Bovill EG, Arkin CF. Effect of lupus anticoagulant on the activated thromboplastin time. Arch Pathol Lab Med 1991; 115: 109-114